<p>Nevirapine is indicated for combination&nbsp;antiretroviral&nbsp;treatment of&nbsp;HIV-1 infection in adults and in pediatric patients 15 days and older.<br />
<br />
Additional important information regarding the use of Nevirapine for the treatment of HIV-1 infection:</p>

<ul>
	<li>Based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled trials, Nevirapine should not be initiated in adult females with CD4+&nbsp;cell counts greater than 250 cells/mm&sup3; or in adult males with CD4+&nbsp;cell counts greater than 400 cells/mm&sup3; unless the benefit outweighs the risk.</li>
	<li>The 14-day lead-in period with Nevirapine 200 mg daily dosing must be strictly followed; it has been demonstrated to reduce the frequency of rash.</li>
	<li>If rash persists beyond the 14-day lead-in period, do not dose escalate to 200 mg twice daily. The 200 mg once-daily dosing regimen should not be continued beyond 28 days, at which point an alternative regimen should be sought.</li>
</ul>